Aart van der Lely

List of Publications by Year
in descending order

46 papers	2,316 citations	471477 17 h-index	254170 43 g-index
47 all docs	47 docs citations	47 times ranked	2668 citing authors

#	Article	IF	Citations
1	Approach to the Patient With Treatment-resistant Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1759-1766.	3.6	10
2	We mind your step: understanding and preventing drop-out in the transfer from paediatric to adult tertiary endocrine healthcare. Endocrine Connections, 2022, 11, .	1.9	4
3	Health Problems in Adults with Praderâ€“Willi Syndrome of Different Genetic Subtypes: Cohort Study, Meta-Analysis and Review of the Literature. Journal of Clinical Medicine, 2022, 11, 4033.	2.4	8
4	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.2	31
5	AST to ALT Ratio and Peripheral Arterial Disease in a Hypertensive Populationâ€”Is There a Link?. Angiology, 2021, 72, 905-907.	1.8	2
6	Towards an Earlier Diagnosis of Acromegaly and Gigantism. Journal of Clinical Medicine, 2021, 10, 1363.	2.4	6
7	Transition readiness among adolescents with rare endocrine conditions. Endocrine Connections, 2021, 10, 432-446.	1.9	5
8	What Every Internist Should Know About Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five-Year Experience of Internal Medicine for Complex Rare Genetic Syndromes. Journal of the Endocrine Society, 2021, 5, A513-A514.	0.2	0
9	Growth Hormone Treatment for Adults With Prader-Willi Syndrome: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3068-3091.	3.6	15
10	The Diagnostic Journey of a Patient with Praderâ€“Willi-Like Syndrome and a Unique Homozygous SNURF-SNRPN Variant; Bio-Molecular Analysis and Review of the Literature. Genes, 2021, 12, 875.	2.4	4
11	Effects of Childhood Multidisciplinary Care and Growth Hormone Treatment on Health Problems in Adults with Prader-Willi Syndrome. Journal of Clinical Medicine, 2021, 10, 3250.	2.4	10
12	Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4734-e4745.	3.6	10
13	Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review. Obesity Reviews, 2021, 22, e13312.	6.5	11
14	Thyroid Function in Adults with Praderâ€“Willi Syndrome; a Cohort Study and Literature Review. Journal of Clinical Medicine, 2021, 10, 3804.	2.4	13
15	Hypogonadism in Adult Males with Prader-Willi Syndromeâ€”Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion. Journal of Clinical Medicine, 2021, 10, 4361.	2.4	16
16	More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. European Journal of Endocrinology, 2021, 185, 525-538.	3.7	32
17	Comment on Moriconi et al. Very-Low-Calorie Ketogenic Diet as a Safe and Valuable Tool for Long-Term Glycemic Management in Patients with Obesity and Type 2 Diabetes. Nutrients 2021, 13, 758. Nutrients, 2021, 13, 3613.	4.1	2
18	What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of â€˜Internal Medicine for Rare Genetic Syndromesâ€™. Journal of Clinical Medicine, 2021, 10, 5457.	2.4	7

#	Article	IF	Citations
19	Hypogonadism in Women with Prader-Willi Syndromeâ€"Clinical Recommendations Based on a Dutch Cohort Study, Review of the Literature and an International Expert Panel Discussion. Journal of Clinical Medicine, 2021, 10, 5781.	2.4	12
20	The tale in evolution: clarity, consistency and consultation, not contradiction and confusion. Pituitary, 2020, 23, 476-477.	2.9	18
21	Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4626-e4637.	3.6	2
22	Eucaloric Very-Low-Carbohydrate Ketogenic Diet in Acromegaly Treatment. New England Journal of Medicine, 2020, 382, 2161-2162.	27.0	9
23	Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1397-e1407.	3.6	3
24	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2964-2974.	3.6	26
25	Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocrine Connections, 2020, 9, 1178-1190.	1.9	27
26	The position of combined medical treatment in acromegaly. Archives of Endocrinology and Metabolism, 2020, 63, 646-652.	0.6	8
27	Shrinkage of pituitary adenomas with pasireotide â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2019, 7, 509-510.	11.4	2
28	ACRODATÂ® and AcroVoice: an insight into a holistic approach to the management of acromegaly. Pituitary, 2019, 22, 647-648.	2.9	0
29	A tale of pituitary adenomas: to NET or not to NET. Pituitary, 2019, 22, 569-573.	2.9	60
30	How to Position Pasireotide LAR Treatment in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1978-1988.	3.6	32
31	Potential antitumour activity of pasireotide on pituitary tumours in acromegaly. Lancet Diabetes and Endocrinology,the, 2019, 7, 425-426.	11.4	20
32	Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. European Journal of Endocrinology, 2019, 181, 173-183.	3.7	12
33	Pegvisomant for acromegaly: does it always works?. Archives of Endocrinology and Metabolism, 2019, 63, 318-319.	0.6	0
34	Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study). Journal of Clinical Endocrinology and Metabolism, 2018, 103, 586-595.	3.6	58
35	The physiology of endocrine systems with ageing. Lancet Diabetes and Endocrinology,the, 2018, 6, 647-658.	11.4	192
36	Development of ACRODATÂ®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary, 2017, 20, 692-701.	2.9	51

#	Article	IF	Citations
37	Pregnancy and acromegaly. Pituitary, 2017, 20, 179-184.	2.9	27
38	Systematic Evaluation of Corticosteroid Use in Obese and Non-obese Individuals: A Multi-cohort Study. International Journal of Medical Sciences, 2017, 14, 615-621.	2.5	20
39	Effect of long-term GH replacement therapy on cardiovascular outcomes in isolated GH deficiency compared with multiple pituitary hormone deficiencies: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults. European Journal of Endocrinology, 2014, 171, 151-160.	3.7	12
40	Expert consensus document: A consensus on the medical treatment of acromegaly. Nature Reviews Endocrinology, 2014, 10, 243-248.	9.6	306
41	Ghrelin: a new treatment for non-alcoholic fatty liver disease?. Endocrine, 2013, 43, 247-248.	2.3	4
42	Hypothesis: Extra-hepatic acromegaly: a new paradigm?. European Journal of Endocrinology, 2011, 164, 11-16.	3.7	55
43	Carcinoid syndrome: diagnosis and medical management. Arquivos Brasileiros De Endocrinologia E Metabologia, 2005, 49, 850-860.	1.3	56
44	Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin. Endocrine Reviews, 2004, 25, 426-457.	20.1	1,057
45	Octreoscan Radioreceptor Imaging. Endocrine, 2003, 20, 307-312.	2.2	54
46	The future of growth hormone antagonists. Current Opinion in Pharmacology, 2002, 2, 730-733.	3.5	7